Tuberculosis medicament resistance related tuberculosis-resisting cytotoxic T lymphocyte (CTL) epitope peptide derived from refflux protein and application thereof

A technology for efflux proteins and epitope peptides, which is applied in the direction of peptides, antibacterial drugs, bacterial antigen components, etc., and can solve the problem of few reports on membrane proteins

Active Publication Date: 2011-10-12
ZHENGZHOU UNIV
View PDF3 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

CD8 currently studied + CTL protein epitopes are mainly concentrated on tuberculosis-specific secreted proteins, such as ESAT-6, CFP-10, CFP-21, MPT64, Ag85 complexes, etc., while for membrane proteins, especially the drug efflux protein CD8+CTL Epitopes are rarely reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tuberculosis medicament resistance related tuberculosis-resisting cytotoxic T lymphocyte (CTL) epitope peptide derived from refflux protein and application thereof
  • Tuberculosis medicament resistance related tuberculosis-resisting cytotoxic T lymphocyte (CTL) epitope peptide derived from refflux protein and application thereof
  • Tuberculosis medicament resistance related tuberculosis-resisting cytotoxic T lymphocyte (CTL) epitope peptide derived from refflux protein and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0019] The anti-tuberculosis CTL epitope peptide derived from the tuberculosis drug resistance-related efflux protein of the present invention is a nonapeptide, and the amino acid sequence of the nonapeptide is:

[0020] P5: Tyr-Leu-Gly-Gly-Thr-Thr-Gly-Pro-Val (YLGGTTGPV) molecular weight: 864.6 (theoretical value: 863.44)

[0021] Or P6: Tyr-Ile-Val-Gly-Phe-Cys-Leu-Leu-Val (YIVGFCLLV) Molecular weight: 1026.7 (theoretical value: 1025.86)

[0022] or P7: Thr-Leu-Thr-Trp-Leu-Phe-Ala-Phe-Val (TLTWLFAFV) molecular weight: 1097.7 (theoretical value: 1097.32)

[0023] or P8: Gly-Leu-Val-Ala-Gly-Leu-Ser-Ala-Val (GLVAGLSAV) molecular weight: 786.7 (theoretical value: 786.7)

[0024] Or P9: Ala-Leu-Gly-Met-Leu-Ile-Ala-Gly-Leu (ALGMLIAGL) molecular weight: 858.7 (theoretical value: 857.81)

[0025] or P10: Met-Leu-Ile-Ala-Gly-Leu-Pro-Cys-Leu (MLIAGLPCL) molecular weight: 930.6 (theoretical value: 930.24)

[0026] or P11: Leu-Leu-Cys-Ala-Ile-Phe-Ala-Glu-Val (LLCAIFAEV) molecular weig...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a tuberculosis medicament resistance related tuberculosis-resisting cytotoxic T lymphocyte (CTL) epitope peptide derived from refflux protein, namely, nonapeptide. The amino acid sequence of the nonapeptide is as follows: P5: YLGGTTGPV, or P6: YIVGFCLLV, or P7: TLTWLFAFV, or P8: GLVAGLSAV, or P9: ALGMLIAGL, or P10: MLIAGLPCL, or P11: LLCAIFAEV, or P12: RLWPTVGCL. Accordingto the invention, the HLA-A*0201 restrictive CTL epitope of a tuberculosis medicament resistance related protein antigen is predicted and analyzed by applying SYFPEITHI, BIMAS and NetCTL1.2 databasesand using an immunoinformatics mean according to a primary structure of the antigen so that the epitope peptide is obtained by virtue of selection, and the identified nonapeptide is not reported in documents. The epitope peptide is identified through an in-vitro enzyme linked immunospot (ELISPOT) experiment; and according to the result, a theoretical basis is provided for developing tuberculosis vaccine based on the medicament resistance related protein antigen and more information is provided for designing a tuberculosis polyepitope peptide vaccine based on mixed T cell epitope.

Description

technical field [0001] The present invention relates to a therapeutic polypeptide vaccine for tuberculosis, in particular to an anti-tuberculosis CTL epitope peptide with therapeutic activity screened out by using the tuberculosis self-resistance-related antigen, and also relates to the application of the peptide in the preparation of a therapeutic polypeptide vaccine for tuberculosis . Background technique [0002] The increasing number of drug-resistant Mycobacterium tuberculosis is an important reason for the resurgence of tuberculosis in recent years. The drug resistance mechanism of Mycobacterium tuberculosis can be divided into natural drug resistance mechanism and acquired drug resistance mechanism. Acquired drug resistance is mainly due to point mutations in resistance-related genes, while natural drug resistance mechanisms are mainly due to cell wall permeability barriers and active efflux pump systems. Therefore, the drug efflux system can be an important therape...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/06A61K39/04A61P31/06
Inventor 祁元明陈飞高艳锋朱宇皇吴亚红陈艳平韩艳林
Owner ZHENGZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap